A Phase 2 interventional study of APT-001 topical ophthalmic ointment (spinosad) and Placebo control for APT-001 topical ophthalmic ointment in Blepharitis, sponsored by Aperta Biosciences, LLC. Not yet recruiting at 2 sites in Guatemala. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.
Sponsored by Aperta Biosciences, LLC · Phase 2, Interventional, and Treatment
The purpose of this study is to establish the clinical efficacy of APT-001 topical therapy 1.8% in patients with blepharitis as compared to placebo, and to establish that the therapeutic is safe and generally well tolerated by patients.
This Phase 2 study is an open-label trial to compare the safety and efficacy of APT-001 1.8% to placebo control for the treatment of blepharitis. The primary objective of the study is to compare the safety and efficacy of APT-001 compared to placebo from Day 1 to Day 15 in patients with blepharitis. The primary efficacy endpoint will be cure based upon collarettes. Safety will be determined by assessing adverse effects related to the treatment.
73 studies on the registry are indexed under Blepharitis; 9 are open to participants now.
This study's planned enrollment of 15 is below the median of 60 across 65 interventional studies indexed under Blepharitis.
Browse Blepharitis studies →Aperta Biosciences, LLC is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
APT-001 topical ophthalmic ointment, administered once
Drug: APT-001 topical ophthalmic ointment (spinosad)
Drug: Placebo control for APT-001 topical ophthalmic ointment
APT-001 topical ophthalmic ointment (spinosad), administered once
Placebo control for APT-001 topical ophthalmic ointment, administered once
Demodex mite killing
Number of living Demodex mites following treatment
Time frame: From enrollment to last visit at 2 weeks
Rate of Collarette Cure
Eyelid collarette score 0
Time frame: From enrollment to last visit at 2 weeks
Rate of Erythema Cure
Erythema Cure Rate
Time frame: From enrollment to last visit at 2 weeks
Average Demodex mite density
Demodex mite density
Time frame: From enrollment to last visit at 2 weeks
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Dec 2026; primary completion for Jan 2027, 1 month later.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Spinosad
Aperta Biosciences, LLC